Combining IRE with anti-CTLA-4 promotes a systemic wave of functional neoantigen-specific T cells that is associated with increased primary tumor regression, deposition of tumor-specific TRM cells in multiple NLTs, and protection from tumor re-challenge. The gene discussed is CTLA4; the disease is neoplasm.